Current research explores two key approaches: (1) gene-based therapies to enhance ApoA-V expression, which may stabilize TG levels in the cerebro-vasculature, and (2) pharmacological agents that mimic its LPL-activating function to potentially reduce stroke risk. Here, APOA5 is linked to Stroke.